Lipid-altering agents Approved agents for dyslipidemia Ezetimibe, a potent inhibitor of cholesterol absorption, has been explored for the treatment of NASH/NAFLD, but conflicting results exist [50,51,52]
Concerning the ApoE4 variant, regardless of AD diagnosis, older adults that are ApoE4 + display a greater level of A accumulation that is not evident in ApoE3 + or ApoE2 + individuals (Lim et al., 2017), and AD patients with the ApoE4 genotype ( +/+ or +/ ) display higher levels of intraneuronal A accumulation compared to controls, indicating a baseline detrimental cognitive effect (Yamazaki et al., 2019)
Individual results can vary
It is ideal if you want to see how your active hormones and stress levels are interacting
Islam et al., 2026)
Its very much like the SELECT trial